|
| Study | Patients | Lesions | Tumor volume or size (median) | Type of mets | Dose | Median FU | LC | OS | Toxicity |
|
| Blomgren et al. (1995) [14] | 14 | 17 | 3–260 mL | CRC (11)
Anal canal (1)
Kidney (1)
Ovarian (1) | 7.7–45 Gy
(1–4 fx) | 9.6 mo | NR-50% response rate | NR | 2 cases of
hemorrhagic
gastritis |
|
| Wulf et al. (2006) [15] | 44 (39 liver
mets) | 51 | 9–355 mL | CRC (23)
Breast (11)
Ovarian (4)
Other (13) | 30–37.5 Gy (3 fx)
26 Gy (1 fx) | 2 yr | 1-yr LC, 92%,
2-yr LC, 66% | 1-yr OS, 72%
2-yr OS, 32% | No grade 2–4
toxicity |
|
| Katz et al. (2007) [16] | 69 | 174 | 0.6–12.5 cm
(2.7 cm) | CRC (20)
Breast (16)
Pancreas (9)
Lung (5)
Other (19) | 30–55 Gy
(5–15 fx) | 14.5 mo | 10-mo LC, 76%,
20-mo LC, 57% | Median survival,
14.5 mo,
6-mo OS, 46%,
12-mo OS, 24% | No grade 3/4
toxicity |
|
van der Pool
et al. (2010) [17] | 20 | 31 | 0.7–6.2 cm
(2.3 cm) | All CRC | 30–37.5 Gy
(3 fx) | 26 mo | 1-yr LC, 100%,
2-yr LC, 74% | Median survival,
34 mo,
1-yr OS, 100%,
2-yr OS, 83% | 2 grade 3 late
liver enzyme
changes,
1 grade 2 rib
fracture |
|
| Chang et al. (2011) [18] | 65 | 102 | 0.6–3088 mL
(30.1 mL) | All CRC | 22–60 Gy
(1–6 fx) | 14.4 mo | 1-yr LC, 62%,
2-yr LC, 45% | 1-yr OS, 72%,
2-yr OS, 38% | 2 grade 3
gastritis,
2 grade 3 elevated liver enzymes. |
|
|
Vautravers-Dewas et al. (2011) [19] | 42 | 62 | 0.7–10 cm
(3.4 cm) | | 40 Gy (4 fx)
45 Gy (3 fx) | 14.3 mo | 2-yr LC, 86% | 2-yr OS, 48% | |
|
| Lanciano et al. (2012) [20] | 30 (23 liver mets) | 41 | 2.29–316 mL
(60.9 mL) | CRC (15)
Breast (3)
Esophagus (1)
GIST (1)
Pancreas (1)
NSCLC (2) | 36–60 Gy (3 fx)
50 Gy (5 fx) | 22 mo | 1-yr LC, 92%,
2-yr LC, 56% | 1-yr OS, 73%,
2-yr OS, 31% | No grade 3/4
toxicity |
|
| Habermehl et al. (2013) [21] | 90 | 138 | 11–333 mL
(62 mL) | CRC (70)
Breast (27)
Pancreas (11)
Ovarian (7)
Lung (6)
Others (16),
by site | 10–30 Gy (1 fx) | 21.7 mo | 87%, 69%, and 59% after 6, 12,
and 18 mo | Median OS 24.3 mo; local PFS was 87%, 70%, and 59% after 6, 12, and 18 mo, respectively | No RILD |
|
